Changes in Calmark's management
Calmark Sweden AB (publ) announced today that interim consultant Peter Larsson assumes the function as CFO, as current CFO Madeleine Skoglund leaves the Company at her own request. At the same time, it is announced that Anna Söderlund will be absent for some time on health grounds and that the Board of Directors today appointed Camilla Arneving as acting CEO.
The changes in Calmark's management are effective as of today November 14, with full authority.
Camilla Arneving has worked for Calmark for four years. As an employee, she has served as Marketing Director since August 2020, is a member of the management team and has a broad understanding of Calmark's operations. Camilla holds a graduate in business administration and has over 25 years of experience from leading positions in marketing and communication across a range of industries.
Peter Larsson is currently Managing Partner and Advisor at Evolvefy and joins the Company as interim CFO. Peter has more than 30 years’ experience of international CEO and CFO positions, mainly in startup and scaleup companies. Peter holds a Master of Business Administration and is experienced in working with global B2B sales and distribution.
An agreement has also been concluded with Hans Richter, Hr – Business Controller AB, who will further strengthen the finance function. Hans has extensive experience in financial reporting and corporate governance, and his activities are currently focused primarily on board involvements.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Camilla Arneving, acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags:
